ATE469220T1 - Antikörper, die krebserkrankungen modifizieren - Google Patents
Antikörper, die krebserkrankungen modifizierenInfo
- Publication number
- ATE469220T1 ATE469220T1 AT05714544T AT05714544T ATE469220T1 AT E469220 T1 ATE469220 T1 AT E469220T1 AT 05714544 T AT05714544 T AT 05714544T AT 05714544 T AT05714544 T AT 05714544T AT E469220 T1 ATE469220 T1 AT E469220T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- cancer
- cancer diseases
- modify cancer
- modify
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54866704P | 2004-02-26 | 2004-02-26 | |
PCT/CA2005/000302 WO2005083064A1 (en) | 2004-02-26 | 2005-02-28 | Cancerous disease modifying antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE469220T1 true ATE469220T1 (de) | 2010-06-15 |
Family
ID=34911008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05714544T ATE469220T1 (de) | 2004-02-26 | 2005-02-28 | Antikörper, die krebserkrankungen modifizieren |
Country Status (15)
Country | Link |
---|---|
US (1) | US7399835B2 (de) |
EP (1) | EP1718737B1 (de) |
JP (1) | JP2008504227A (de) |
CN (1) | CN1934246A (de) |
AT (1) | ATE469220T1 (de) |
AU (1) | AU2005217008A1 (de) |
CA (1) | CA2557093A1 (de) |
DE (1) | DE602005021459D1 (de) |
DK (1) | DK1718737T3 (de) |
ES (1) | ES2345260T3 (de) |
NZ (1) | NZ549409A (de) |
PL (1) | PL1718737T3 (de) |
PT (1) | PT1718737E (de) |
SI (1) | SI1718737T1 (de) |
WO (1) | WO2005083064A1 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7947496B2 (en) * | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20080213169A1 (en) * | 2003-04-14 | 2008-09-04 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
US20080025977A1 (en) * | 2003-04-14 | 2008-01-31 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
US20060140963A1 (en) * | 2003-04-14 | 2006-06-29 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
US7411046B2 (en) * | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
US7452979B2 (en) * | 2005-08-02 | 2008-11-18 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7494648B2 (en) * | 2005-08-02 | 2009-02-24 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
US7456259B2 (en) * | 2005-08-02 | 2008-11-25 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7452978B2 (en) * | 2005-08-02 | 2008-11-18 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7456258B2 (en) * | 2005-08-02 | 2008-11-25 | Arius Research, Inc. | Cancerous disease modifying antibodies |
CN101535471B (zh) * | 2006-11-13 | 2011-06-29 | 霍夫曼-拉罗奇有限公司 | 修饰癌症病的抗体180706-02 |
CN101668849A (zh) * | 2007-03-26 | 2010-03-10 | 霍夫曼-拉罗奇有限公司 | 由杂交瘤细胞系ar51a630.3产生的减轻癌性疾病的抗体010207-01 |
CN101687931A (zh) * | 2007-07-16 | 2010-03-31 | 霍夫曼-拉罗奇有限公司 | 抗癌细胞毒性单克隆抗体 |
WO2012106281A2 (en) | 2011-01-31 | 2012-08-09 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
EP2877572B1 (de) | 2012-07-24 | 2018-11-28 | The General Hospital Corporation | Onkolytische virustherapie für resistente tumoren |
US9605074B2 (en) * | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4433059A (en) * | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
NZ222509A (en) | 1986-11-19 | 1993-03-26 | Oncogen | Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen |
US4861581A (en) | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US5171665A (en) | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
DE69229254T2 (de) | 1991-10-30 | 1999-09-23 | Idemitsu Kosan Co | Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper |
IL105008A0 (en) | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
DE69432926T2 (de) | 1993-02-05 | 2004-05-13 | Epigen, Inc., Wellesley | Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy |
WO1996000084A1 (en) | 1994-06-24 | 1996-01-04 | Torchilin Vladimir P | Use of autoantibodies for tumor therapy and prophylaxis |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US7009040B2 (en) * | 2003-01-21 | 2006-03-07 | Arius Research, Inc. | Cancerous disease modifying antibodies |
AU2002327704A1 (en) * | 2001-09-21 | 2003-04-01 | Raven Biotechnologies, Inc. | Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof |
WO2003048301A2 (en) | 2001-10-11 | 2003-06-12 | Protein Design Labs Inc. | Anti-hla-dr antibodies and the methods of using thereof |
AU2003227148A1 (en) | 2002-04-05 | 2003-10-27 | Arius Research, Inc. | Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer |
US20060140963A1 (en) | 2003-04-14 | 2006-06-29 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
-
2005
- 2005-02-25 US US11/067,366 patent/US7399835B2/en not_active Expired - Fee Related
- 2005-02-28 JP JP2007500025A patent/JP2008504227A/ja active Pending
- 2005-02-28 CN CNA2005800060181A patent/CN1934246A/zh active Pending
- 2005-02-28 ES ES05714544T patent/ES2345260T3/es active Active
- 2005-02-28 PL PL05714544T patent/PL1718737T3/pl unknown
- 2005-02-28 PT PT05714544T patent/PT1718737E/pt unknown
- 2005-02-28 DE DE602005021459T patent/DE602005021459D1/de active Active
- 2005-02-28 AT AT05714544T patent/ATE469220T1/de active
- 2005-02-28 EP EP05714544A patent/EP1718737B1/de not_active Not-in-force
- 2005-02-28 WO PCT/CA2005/000302 patent/WO2005083064A1/en active Application Filing
- 2005-02-28 CA CA002557093A patent/CA2557093A1/en not_active Withdrawn
- 2005-02-28 AU AU2005217008A patent/AU2005217008A1/en not_active Abandoned
- 2005-02-28 SI SI200531076T patent/SI1718737T1/sl unknown
- 2005-02-28 NZ NZ549409A patent/NZ549409A/en unknown
- 2005-02-28 DK DK05714544.3T patent/DK1718737T3/da active
Also Published As
Publication number | Publication date |
---|---|
AU2005217008A1 (en) | 2005-09-09 |
DK1718737T3 (da) | 2010-08-09 |
PL1718737T3 (pl) | 2010-10-29 |
CA2557093A1 (en) | 2005-09-09 |
EP1718737A4 (de) | 2007-03-28 |
ES2345260T3 (es) | 2010-09-20 |
EP1718737A1 (de) | 2006-11-08 |
NZ549409A (en) | 2009-12-24 |
JP2008504227A (ja) | 2008-02-14 |
US20050191305A1 (en) | 2005-09-01 |
EP1718737B1 (de) | 2010-05-26 |
US7399835B2 (en) | 2008-07-15 |
CN1934246A (zh) | 2007-03-21 |
PT1718737E (pt) | 2010-08-09 |
WO2005083064A1 (en) | 2005-09-09 |
DE602005021459D1 (de) | 2010-07-08 |
SI1718737T1 (sl) | 2010-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE469220T1 (de) | Antikörper, die krebserkrankungen modifizieren | |
WO2007095749A8 (en) | Cytotoxicity mediation of cells evidencing surface expression of trop-2 | |
CY1106455T1 (el) | Τροποποιητικα αντισωματα καρκινικης νοσου | |
MX2009007619A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
WO2004065422A3 (en) | Cancerous disease modifying antibodies | |
BRPI0601736A (pt) | métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais | |
MX2009001015A (es) | Anticuerpos modificadores de enfermedad cancerosa. | |
MX2009007618A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
MX2009007617A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
WO2005012361A3 (en) | Antibodies raised against colon carcinomas | |
WO2003086456A3 (en) | Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer | |
BR0309226A (pt) | Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável | |
ATE483028T1 (de) | Antikörper, die krebserkrankungen modifizieren | |
DE60331827D1 (de) | Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren | |
MX2009011667A (es) | Anticuerpos de modificacion de enfermedad cancerosa. | |
MX2009009919A (es) | Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma. | |
MX2009001292A (es) | Anticuerpos modificadores de enfermedad cancerosa. | |
DK1360208T3 (da) | Fremgangsmåde til fremstilling af cytotoksiske anticancer-antistoffer | |
WO2008058380A8 (en) | Cancerous disease modifying antibodies | |
AR070279A1 (es) | Anticuerpos modificadores de enfermedades cancerosas (cdma) | |
NO20091459L (no) | Cancerose sykdomsmodifiserende antistoffer | |
BRPI0718609A8 (pt) | Anticorpos modificadores de doença cancerosa. | |
AR072750A1 (es) | Anticuerpos modificadores de enfermedades cancerosas | |
AR070280A1 (es) | Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab) | |
AR071847A1 (es) | Anticuerpos monoclonales modificadores de enfermedades cancerosas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1718737 Country of ref document: EP |